Is Celltrion (068270) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 4.7% / 30% | 2.5% / 30% | 2.6% / 30% | 0.94% / 5% | ✓ HALAL |
| DJIM | 4.7% / 33% | 2.5% / 33% | 2.6% / 33% | 0.94% / 5% | ✓ HALAL |
| MSCI | 10.4% / 33% | 5.4% / 33% | 5.8% / 33% | 0.94% / 5% | ✓ HALAL |
| S&P | 4.7% / 33% | 2.5% / 33% | 2.6% / 33% | 0.94% / 5% | ✓ HALAL |
| FTSE | 10.4% / 33% | 5.4% / 33% | 5.8% / 50% | 0.94% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 59.3% | |
| Operating Margin | 35.4% | |
| Net Margin | 24.7% | |
| Return on Equity (ROE) | 5.9% | |
| Return on Assets (ROA) | 3.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $646.1B |
| Free Cash Flow | $314.3B |
| Total Debt | $3.7T |
| Debt-to-Equity | 21.5 |
| Current Ratio | 1.4 |
| Total Assets | $22.3T |
Price & Trading
| Last Close | KRW 203,000.00 |
| 50-Day MA | KRW 217,316.00 |
| 200-Day MA | KRW 188,341.50 |
| Avg Volume | 805K |
| Beta | 0.3 |
|
52-Week Range
KRW 144,615.39
| |
About Celltrion (068270)
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. The company is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. It distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Purification Calculator
As a halal stock with 0.94% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Celltrion (068270) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Celltrion is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Celltrion's debt ratio?
Celltrion's debt ratio is 4.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 10.4%.
Does Celltrion require dividend purification?
Yes, Celltrion has an impermissible income ratio of 0.94%, which means 0.94% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Celltrion's key financial metrics?
Celltrion has a market capitalization of $45.1T, and revenue of $4.2T. The company maintains a gross margin of 59.3% and a net margin of 24.7%. Return on equity stands at 5.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.